BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ambion Diagnostics Announces Continued Alliance With Wyeth Pharmaceuticals (WYE) For The Development And Supply Of RNA For Vaccine Production


10/19/2005 5:12:57 PM

AUSTIN, Texas, March 8 /PRNewswire/ -- Ambion Diagnostics, a division of Ambion, Inc., has entered into a new agreement with Wyeth Pharmaceuticals, a world leader in vaccine products, to continue its alliance in the development and supply of cGMP-grade RNA that will be incorporated as a component in Wyeth's innovative vaccine program. Ambion Diagnostics will manufacture RNA transcripts according to QSR guidelines and will supply the material at a scale sufficient to meet Wyeth's requirements for phase I/II clinical trials.

This agreement represents a significant milestone towards Ambion's goal of establishing leadership in the area of contract development and manufacturing services for RNA-based applications. Under terms of the new agreement, Ambion Diagnostics will optimize synthesis and purification of very long RNA molecules suitable for use in the production of human therapeutics. Subsequent manufacture of the RNA transcripts will be performed in Ambion's state-of-the-art cGMP facilities.

"We are very pleased that Wyeth has continued its alliance with Ambion Diagnostics. Our ongoing collaboration on the development and supply of cGMP- RNA for new vaccine targets indicates the success of this relationship," said Jeff Williams, Ph.D., General Manager of Ambion Diagnostics.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth , has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, hemophilia, oncology and vaccines. Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide.

About Ambion Diagnostics

Ambion Diagnostics (http://www.ambiondx.com/ ), a division of Ambion, Inc., develops, manufactures and markets innovative products to detect diseases and enable the development of pharmaceuticals. It leverages the core technologies and RNA expertise of Ambion's Research Product Division to provide solutions for the clinical and healthcare industries. Ambion Diagnostics' have demonstrated reproducibility and dependability of its validated cGMP processes. With a commitment to quality, Ambion Diagnostics is QSR/ISO compliant and FDA registered.

Contact: Cindy R. WalkerPeach, Ph.D. Director, Development & cGMP Operations Ambion Diagnostics Ambion, Inc. (512) 651-0200

Ambion Diagnostics

CONTACT: Cindy R. WalkerPeach, Ph.D., Director, Development & cGMPOperations of Ambion Diagnostics and Ambion, Inc., +1-512-651-0200



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES